Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

NICE is designing Health Technology Assessment innovation Laboratory (HTA Lab) in England

On June 15, 2022, the National Institute for Health and Care Excellence (NICE) announced designing Health Technology Assessment innovation Laboratory (HTA Lab), a new collaborative space for research and development.

Using collaborative and innovative approaches, the HTA Lab will enable NICE to work with the stakeholders and develop solutions to complex HTA issues, such as disruptive new health technologies and broader methods, processes, and policy issues. It will help drive solutions to current and future health challenges, taking innovation from the lab into practice.

The HTA Lab will use a "sandbox" approach to developing solutions to complex HTA problems. The "sandbox" concept was initiated in the financial sector to provide a safe space for businesses to push the boundaries and innovate new products and ways of working. Thus, explore approaches that may not fit within existing practices but have the potential for significant benefits if adopted as standard practice.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).